MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Bibliographic Details
Title: MYCN amplification and ATRX mutations are incompatible in neuroblastoma
Authors: Maged Zeineldin, Sara Federico, Xiang Chen, Yiping Fan, Beisi Xu, Elizabeth Stewart, Xin Zhou, Jongrye Jeon, Lyra Griffiths, Rosa Nguyen, Jackie Norrie, John Easton, Heather Mulder, Donald Yergeau, Yanling Liu, Jianrong Wu, Collin Van Ryn, Arlene Naranjo, Michael D. Hogarty, Marcin M. Kamiński, Marc Valentine, Shondra M. Pruett-Miller, Alberto Pappo, Jinghui Zhang, Michael R. Clay, Armita Bahrami, Peter Vogel, Seungjae Lee, Anang Shelat, Jay F. Sarthy, Michael P. Meers, Rani E. George, Elaine R. Mardis, Richard K. Wilson, Steven Henikoff, James R. Downing, Michael A. Dyer
Source: Nature Communications, Vol 11, Iss 1, Pp 1-20 (2020)
Publisher Information: Nature Portfolio, 2020.
Publication Year: 2020
Collection: LCC:Science
Subject Terms: Science
More Details: In most cancers, mutations that lead to oncogene activation and tumor suppressor inactivation synergize to promote tumorigenesis. However, in neuroblastomas, MYCN amplification and ATRX mutations are mutually exclusive and incompatible.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2041-1723
Relation: https://doaj.org/toc/2041-1723
DOI: 10.1038/s41467-020-14682-6
Access URL: https://doaj.org/article/08a87c1bf95d4f798e9e0d5a7daabd61
Accession Number: edsdoj.08a87c1bf95d4f798e9e0d5a7daabd61
Database: Directory of Open Access Journals
More Details
ISSN:20411723
DOI:10.1038/s41467-020-14682-6
Published in:Nature Communications
Language:English